Important Considerations Beyond Systemic Efficacy
As survival outcomes improve in mNSCLC, patients are spending more time on therapy1
When treating patients with ALK+ mNSCLC in the first-line, secondary treatment goals such as long-term tolerability and patient preference regarding dose regimens have become increasingly important in overall disease management.1-3
Which of these other considerations is a top priority for you?
Once-daily dosing can substantially reduce a patient’s pill burden4
up to 365 tablets / capsules a yeara
up to 730 tablets / capsules a yeara
up to 2,920 tablets / capsules a yeara
ALUNBRIG® (brigatinib) offers 1 tablet, once-daily dosing or 365 pills per year with or without food4
National Comprehensive Cancer Network® (NCCN®): recommends brigatinib as a Category 1, preferred first-line treatment option for ALK+ metastatic NSCLC5,b,c,d
Learn how to get your patient started on ALUNBRIG® (brigatinib)
bWhen an ALK rearrangement is discovered prior to first-line systemic therapy.5
cThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.
dSee the NCCN Guidelines® for detailed recommendations, including other preferred treatment options.
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; mNSCLC, metastatic NSCLC; NSCLC, non-small cell lung cancer.